

## Material Information (3176 MEDIGEN?????)

SEQ_NO	1	Date of announcement	2025/03/26	Time of announcement	16:51:18
Subject	Japan Patent Granted for OBP-301 Administration Method				
Date of events	2025/03/26	To which item it meets	paragraph 53		
Statement	<p>1.Date of occurrence of the event:2025/03/26</p> <p>2.Company name:Medigen Biotechnology Corp.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: Medigen Biotechnology Corp. and the Japanese publicly traded company Oncolys BioPharma ("Oncolys", TSE stock code 4588), are jointly developing the oncolytic virus new drug OBP-301 (Telomelysin). Oncolys announced today (March 26, 2025) that the patent filed in Japan on May 14, 2020, with application number 2021-519474, titled "Method for Administering Oncolytic Virus to Tumor Tissue, and Device for Administration", has been granted by the Japan Patent Office. The patent term will expire in May 2040.</p> <p>6.Countermeasures:none</p> <p>7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):</p> <p>(1)The development timeline for new drugs is long, the investment costs are high, and success is not guaranteed. These factors may pose risks to investors, who should make careful judgments and invest cautiously.</p> <p>(2)Our company shares the development costs of OBP-301 with Japan's Oncolys and will share in the future commercial benefits.</p> <p>(3)Link to the announcement from Japan's Oncolys: <a href="https://ssl4.eir-parts.net/doc/4588/tdnet/2584979/00.pdf">https://ssl4.eir-parts.net/doc/4588/tdnet/2584979/00.pdf</a></p>				